SBFM Q1 2024 Earnings — Sunshine Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

SBFMSunshine Biopharma, Inc.

$6M

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$8M+54.1% YoY

Gross Profit

$2M30.7% margin

Operating Income

-$1M-17.9% margin

Net Income

-$1M-17.0% margin

EPS (Diluted)

$-40.04

QoQ Revenue Growth

-1.8%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$4M

Stock-Based Comp.

$12,000

Balance Sheet

Total Assets

$32M

Total Liabilities

$7M

Stockholders' Equity

$25M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$5M	+54.1%
Gross Profit	$2M	$2M	+26.5%
Operating Income	-$1M	-$2M	+26.1%
Net Income	-$1M	-$2M	+24.6%